Mia's Feed
Medical News & Research

Enhancing Accessibility to Clinical Trials for Cardiomyopathy Patients

Enhancing Accessibility to Clinical Trials for Cardiomyopathy Patients

Share this article

The American Heart Association is launching a new initiative to improve access, awareness, and participation in clinical trials for cardiomyopathy, focusing on underserved populations and emerging gene-editing therapies.

2 min read

Despite significant scientific progress in cardiovascular medicine, many individuals living in rural and underserved communities continue to face obstacles in accessing advanced therapies, such as gene editing for cardiomyopathy. According to a 2020 American Heart Association advisory, these disparities hinder equitable healthcare delivery. To bridge these gaps, the American Heart Association is leveraging its 'Get With The Guidelines' data to support populations that are often underrepresented in clinical research. This program aligns hospitals with current evidence-based guidelines and precision measurement tools to elevate care quality.

Aiming to improve diagnosis, treatment, and outcomes for cardiomyopathy, the organization has launched an initiative focused on gene-editing therapies for transthyretin amyloid cardiomyopathy (ATTR-CM). This progressive and often underdiagnosed heart condition involves abnormal accumulation of transthyretin protein in the heart, disrupting its ability to relax and fill properly, which can eventually lead to heart failure.

The initiative seeks to close knowledge gaps, raise awareness, and improve access to early diagnosis and emerging treatments regardless of geographical location through research, education, and community outreach. With financial backing from Intellia Therapeutics, the program emphasizes increasing understanding of gene editing, advancing research, and expanding clinical trial opportunities among traditionally excluded populations.

According to Dr. Michelle Kittleson, the campaign aims to ensure that the latest medical innovations are accessible to all, fostering trust and participation across diverse communities. The initiative features a comprehensive education campaign, including a series of webinars, with the first scheduled for June 18, titled 'Understanding Amyloidosis & Emerging Therapeutic Frontiers.' It will feature leading experts in cardiology and gene therapy.

Additional efforts include enhancing patient identification systems, developing referral networks, and creating tools that utilize clinical data to identify eligible trial participants. These steps are designed to improve patient enrollment in innovative therapies and clinical research, ultimately contributing to better care and outcomes for those affected by cardiomyopathy.

This ongoing effort aligns with the American Heart Association’s broader mission to improve cardiovascular health equity and ensure that advancements in treatment reach all populations, especially those currently underserved.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

New Insights into Key Genes Driving Colon Cancer Progression

Recent research highlights the critical role of the SOX9 gene in suppressing colon cancer progression and metastasis, revealing potential targets for future therapies.

Breakthrough in Breast Cancer Treatment: Dimeric VIPR2 as a Promising Target

Hiroshima University researchers identify VIPR2 receptor dimerization as a key factor in breast cancer progression, paving the way for targeted therapies that inhibit tumor growth and metastasis.